The significant growth in investment value over 15 years, coupled with a strong average annual return of 20.43%, indicates a positive outlook for Edwards Lifesciences. This historical performance, especially in a company with a substantial market cap of $52.37 billion, suggests a strong foundation and potential for continued growth, making it likely to positively influence investor sentiment and potentially the stock price in the short term.